Opus Genetics Delivers Multiple Positive Milestones; CMC and Runway Risks Diminish

What happened

Opus Genetics reported Q3 2026 results with several key pipeline advances: OPGx-BEST1 Cohort 2 dosing is complete with data expected in Q1 2027, OPGx-LCA5 registrational Phase 3 is fully enrolled with dosing initiation expected in Q4 2026, FDA cleared the IND for OPGx-RDH12 with Phase 1/2 dosing planned for Q4 2026, and FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia triggered a milestone payment. The company now expects cash runway into 2029, a substantial extension from the prior 'into 2H27' guidance, easing near-term financing concerns that had anchored our WAIT rating. Importantly, full enrollment of the LCA5 Phase 3 trial and imminent dosing suggests the previously identified CMC supply gate has been resolved, removing a key thesis breaker. These developments were not fully reflected in our last report, which assigned a base-case implied value of $3.40 and a bull case of $5.20 based on 2026 catalyst confidence. The new information shifts probability mass toward the bull scenario and supports a positive reassessment of the investment case.

Implication

Over a 12-month horizon, the extended runway and expanded pipeline increase the probability of achieving multiple clinical inflection points without dilutive financing; however, clinical outcomes for LCA5 and BEST1 remain binary, and the stock may re-rate further on positive data but could correct sharply if data disappoint. Maintain a disciplined position size given still-early-stage and execution risks.

Thesis delta

The prior WAIT rating was driven by the gating of LCA5 Phase 3 dosing on validated commercial-process supply and uncertainty around runway/dilution. The Q3 2026 update indicates the LCA5 pivotal trial is fully enrolled with dosing expected in Q4 2026, implying the CMC hurdle has been cleared, and management now guides cash runway into 2029, materially reducing near-term financing risk. As a result, the probability of the bull scenario increases, and we would consider upgrading the rating to a positive stance pending confirmation of dosing initiation and cash balance details in the 10-Q.